The role of bisphosphonates in the treatment of prostate cancer.
Parker
Christopher C
CC
The Academic Department of Radiotherapy & Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Chris.Parker@icr.as.uk
D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary*; D017326:Clinical Trials, Phase III as Topic; D004002:Clodronic Acid / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D004164:Diphosphonates; D007093:Imidazoles; D004002:Clodronic Acid; D000077211:Zoledronic Acid